Adocia
Adocia
ADOC
EURONEXT
5.89
EUR
18.51%
About
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use.
The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram.
Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 70.1K |
| Three Month Average Volume | 2.6M |
| High Low | |
| Fifty-Two Week High | 12.66 EUR |
| Fifty-Two Week Low | 5.11 EUR |
| Fifty-Two Week High Date | 27 Dec 2023 |
| Fifty-Two Week Low Date | 15 Jul 2024 |
| Price and Volume | |
| Current Price | 5.89 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.51% |
| Thirteen Week Relative Price Change | -30.31% |
| Twenty-Six Week Relative Price Change | -33.46% |
| Fifty-Two Week Relative Price Change | -51.96% |
| Year-to-Date Relative Price Change | -49.65% |
| Price Change | |
| One Day Price Change | -2.81% |
| Thirteen Week Price Change | -33.37% |
| Twenty-Six Week Price Change | -36.05% |
| Five Day Price Change | 1.90% |
| Fifty-Two Week Price Change | -49.66% |
| Year-to-Date Price Change | -48.96% |
| Month-to-Date Price Change | -2.81% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.49079 EUR |
| Book Value Per Share (Most Recent Quarter) | -0.49079 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.49143 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.49143 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.24046 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.19403 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.19403 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.90983 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.93109 EUR |
| Normalized (Last Fiscal Year) | -1.90983 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.90983 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.93109 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -1.90983 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -1.93109 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.92004 EUR |
| Cash Per Share (Most Recent Quarter) | 0.92004 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -1.86479 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -1.86479 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.4609 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -408 |
| Cash Flow Revenue (Trailing Twelve Months) | -238 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -984.19% |
| Pretax Margin (Last Fiscal Year) | -984.19% |
| Pretax Margin (5 Year) | -528.16% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 64.42% |
| Gross Margin (Trailing Twelve Months) | 7.91% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -662.51% |
| Operating Margin (Trailing Twelve Months) | -662.51% |
| Operating Margin (5 Year) | -435.38% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -984.28% |
| Net Profit Margin (Trailing Twelve Months) | -984.28% |
| Net Profit Margin (5 Year) | -514.53% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -87.24% |
| Revenue Growth (3 Year) | -46.13% |
| Revenue Change (Trailing Twelve Months) | -81.22% |
| Revenue Per Share Growth | -50.98% |
| Revenue Growth (5 Year) | 36.74% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -27.60% |
| Total Debt (5 Year) | 13.59% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 32.04% |
| EPS Change (Trailing Twelve Months) | -148.31% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 127.0K |
| Net Debt (Last Fiscal Year) | 127.0K |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 41 |
| Price to Sales (Trailing Twelve Months) | 41 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,107,000 |
| Free Cash Flow (Trailing Twelve Months) | -5,107,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 |
| Net Interest Coverage (Trailing Twelve Months) | -2 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -76.16% |
| Return on Assets (Trailing Twelve Months) | -76.16% |
| Return on Assets (5 Year) | -43.08% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -342.79% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -396.14% |
| Return on Investment (Trailing Twelve Months) | -396.14% |
| Return on Investment (5 Year) | -72.93% |